Our findings demonstrate that coordinated PR rapid and nonclassical transcriptional effects govern breast cancer growth and offer novel mechanistic insight into one of the major challenges in the clinical management of breast cancer: endocrine therapy resistance. The gene discussed is PGR; the disease is breast cancer.